NCT05706298 (EXTOD-Active) is a NA clinical trial of Active Breaks in Type 1 Diabetes, sponsored by Liverpool John Moores University.

Who is sponsoring NCT05706298?

NCT05706298 is sponsored by Liverpool John Moores University.

What drugs are being tested in NCT05706298?

Interventions in NCT05706298: Active Breaks.

What condition does NCT05706298 study?

NCT05706298 studies Type 1 Diabetes.

Is NCT05706298 still recruiting?

NCT05706298 is currently status unknown. Last updated 10 October 2023.

Last reviewed 2023-10-10 · How we verify

NCT05706298: EXTOD-Active

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Active Breaks in People With Type 1 Diabetes

Status unknown NA Last updated 10 October 2023

What this trial tests

NA trial testing Active Breaks in Type 1 Diabetes in 118 participants. Status unknown.

Timeline

7 December 2022

Primary endpoint
1 August 2024

1 August 2024

Quick facts

Lead sponsor	Liverpool John Moores University
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	118
Start date	7 December 2022
Primary completion	1 August 2024
Estimated completion	1 August 2024
Sites	1 location across United Kingdom

Drugs / interventions tested

Active Breaks

Conditions studied

Type 1 Diabetes — all drugs for Type 1 Diabetes →

Sponsor

Liverpool John Moores University

Who can join

Adults 18 to 66, any sex, with Type 1 Diabetes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

the investigators aim to determine the effect of 4 weeks of frequent active breaks from prolonged sitting on time in target glycaemic range in people with type 1 diabetes with high habitual sedentary behaviour.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Can 4 weeks of real-world active breaks improve glycaemic management in sedentary adults with type 1 diabetes? The EXTOD-Active randomised control trial protocol.
Jenkins JG, Cocks M, Narendran P, Andrews RC, et al · · 2025 · PMID 40195972 · DOI 10.1136/bmjsem-2025-002594

Verify or expand the search:

Other recruiting trials for Type 1 Diabetes

Currently open trials in the same condition.

NCT07061574 — A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New On · Phase 1, PHASE2 · recruiting
NCT07360080 — Long-Term Outcomes of Teplizumab in Routine Clinical Care · recruiting
NCT07457580 — Real-World Study of Patients With Type 1 Diabetes Treated With Teplizumab as Part of Managed Access Programs (MAPs) · recruiting
NCT07212179 — Safety and Feasibility of a Self-Learning Bolus Calculator With Simplified Meal Announcement in Adolescents With Type 1 · NA · recruiting
NCT07287943 — To Study the Efficacy and Safety of Medtronic 780G Insulin Pump in People With Gastroparesis and Type 1 Diabetes. · NA · recruiting

Other Liverpool John Moores University trials

Trials by the same sponsor.

NCT07454317 — Biofeedback Intervention for Paroxysmal Atrial Fibrillation · NA · not yet recruiting
NCT07469852 — Effects of Caffeine Ingestion on Morning Cognitive and 4-km Time Trial Performance in Males · Phase 1, PHASE2 · active not recruiting
NCT07366931 — The Effect of Daily Supplementation With Humiome® Post LB on Gastrointestinal Symptoms in Female Athletes · Phase 1, PHASE2 · not yet recruiting
NCT07466732 — Effects of Caffeine Ingestion on Morning Cognitive and Muscle Repeated Sprint Performance in Males · EARLY_PHASE1 · enrolling by invitation
NCT07341243 — Exercising in Hot Conditions: How Does it Effect Blood Glucose in People With T1D · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05706298 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Liverpool John Moores University
Last refreshed: 10 October 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05706298.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing